{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T07:57:01Z","timestamp":1774166221194,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.critrevonc.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T14:39:36Z","timestamp":1517582376000},"page":"52-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy"],"prefix":"10.1016","volume":"123","author":[{"given":"A.","family":"Casadei Gardini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rosetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valgiusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ruscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.L.","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2018.01.007_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","article-title":"Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal","volume":"87","author":"Ajani","year":"1989","journal-title":"Am. J. Med."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0010","series-title":"SEER Cancer Statistics Review 1975\u20132007","author":"Altekruse","year":"1975"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0015","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03233711."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1\u2013expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0025","first-page":"373","article-title":"Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer","volume":"382","author":"Bakema","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000341371","article-title":"Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer","volume":"5","author":"Barmettler","year":"2012","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/bjc.2016.144","article-title":"Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection","volume":"114","author":"Cacheux","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0045","doi-asserted-by":"crossref","first-page":"37621","DOI":"10.1038\/srep37621","article-title":"No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)","volume":"6","author":"Capelli","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0050","doi-asserted-by":"crossref","first-page":"e92071","DOI":"10.1371\/journal.pone.0092071","article-title":"KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)","volume":"9","author":"Casadei Gardini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(04)01410-X","article-title":"Cancer of the anal canal","volume":"5","author":"Clark","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0060","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0065","first-page":"861","article-title":"5-fluorouracil and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0070","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.molimm.2009.05.009","article-title":"Cancer resistance to complementdependent cytotoxicity (CDC): Problem-oriented research and development","volume":"46","author":"Gancz","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0075","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0085","first-page":"33","article-title":"Programmed cell death-Ligand 1 (PD -L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC)","author":"Gujja","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00000421-199312000-00017","article-title":"5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal","volume":"16","author":"Jaiyesimi","year":"1993","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0100","first-page":"1345","article-title":"Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases","volume":"70","author":"Khater","year":"1986","journal-title":"Cancer Treat. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.01.007_bib0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000452766","article-title":"EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-Institution experience","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0110","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","article-title":"Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer","volume":"51","author":"Leon","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","article-title":"Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status","volume":"77","author":"Lukan","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0120","first-page":"221","article-title":"The immune microenvironment and HPV in anal cancer: rationale to complement chemoradiation with immunotherapy","volume":"1868","author":"Martin","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.soc.2016.07.001","article-title":"Epidemiology of anal canal cancer","volume":"26","author":"Nelson","year":"2017","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0145","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/cncr.28045","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"119","author":"Olivatto","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0150","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0155","doi-asserted-by":"crossref","first-page":"e965570","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"Oncoimmunology"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2018.01.007_bib0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0165","first-page":"E82","article-title":"Cetuximab in combination with cisplatin and 5-fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal","volume":"6","author":"Rogers","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","article-title":"Epidermal growth factor receptor inhibition in metastatic anal cancer","volume":"27","author":"Rogers","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.01.007_bib0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS malignancy consortium trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841869309083882","article-title":"Treatment of relapsing anal carcinoma","volume":"32","author":"Tanum","year":"1993","journal-title":"Acta Oncol."},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2018.01.007_bib0185","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.critrevonc.2018.01.007_bib0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00280-009-1117-3","article-title":"K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment","volume":"65","author":"Zampino","year":"2009","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817304419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817304419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T12:25:17Z","timestamp":1535113517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817304419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":38,"alternative-id":["S1040842817304419"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}